Colestipol-induced hepatotoxicity.
A 65-year-old man with type IIa dyslipidemia who received flavored colestipol granules 2 scoops/day for 3 months developed asymptomatic hepatotoxicity. Several of his liver enzymes were elevated 10 times the upper limit of normal. One week after discontinuing colestipol, serum transaminases fell dramatically, with some returning to normal limits. Four weeks after colestipol was discontinued, all liver function tests were normal. Rechallenge was not attempted. Other potential causes of hepatocellular injury were evaluated. Bile acid-binding resins commonly are administered to treat type IIa dyslipidemia. Despite extensive use of the resins, significant elevations of transaminase levels are rare. Because the exact mechanism of bile acid resin-induced hepatotoxicity is unknown, high-risk patients may require liver function test monitoring and education on hepatotoxic side effects.
Sirmans
S M
SM
Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA.
Beck
J K
JK
Banh
H L
HL
Freeman
D A
DA
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology*; D003084:Colestipol / Q000009:adverse effects*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008297:Male; D000637:Transaminases / Q000378:metabolism*
D000960:Hypolipidemic Agents; D000637:Transaminases; D003084:Colestipol